Compare Enbridge Inc (ENB) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Moderna, Inc. — how do they compare? Enbridge Inc trades at $51.78 (market cap $112.62B), while Moderna, Inc. trades at $63.74 (market cap $24.18B). The key difference: Enbridge Inc is far larger — about 4.7× Moderna, Inc.'s market cap, and Enbridge Inc pays a 5.34% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| ENB | MRNA | |
|---|---|---|
Market Cap | $112.62B | $24.18B |
Sector | Energy | Health |
52-Week High | $58.04 | $81.80 |
52-Week Low | $45.23 | $22.36 |
Enterprise Value | $196.53B | $20.33B |
Dividend Yield | 5.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $51.39, up 0.21% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $65.2B revenue, 11.5% net margin, and consistent dividend growth spanning 31 years. Recent Q2 2026 results exceeded expectations with $0.46 EPS versus $0.43 estimate, supported by robust pipeline and utility performance. Analyst sentiment is balanced with 48% buy ratings while technical indicators show oversold conditions with RSI at 14.8.
ENB presents a compelling income opportunity with 5.3% dividend yield and $41B growth pipeline, though faces regulatory risks from Line 5 litigation and Wisconsin tribal land dispute. The stock's current valuation at 27.8x P/E appears reasonable given stable cash flows, but investors should monitor debt levels approaching 49% of assets and potential project delays affecting growth execution.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
